NFKB1 and melanoma: Furthermore, the combination of a TNFα blocking antibody and PLX4720 further reduced the cell viability of Mel-CV.S and Mel-CV, suggesting that autocrine TNFα driven by RIP1-NF-κB signaling as shown previously may contribute to resistance of melanoma cells to BRAF inhibitors (Fig. S1)13.